
HK inno.N's gastroesophageal reflux disease treatment K-CAB (tegoprazan) has received marketing approval in Brazil, bringing the total number of countries where the drug is approved to 25.
HK inno.N said Tuesday that Brazil's National Health Surveillance Agency (ANVISA) recently granted marketing approval for K-CAB.
K-CAB will become the first potassium-competitive acid blocker (P-CAB) developed in South Korea to be launched in Brazil. Brazil is the largest pharmaceutical market in Latin America, with its local market for drugs used to treat peptic ulcers estimated at around 1.1 trillion won in 2025.
HK inno.N plans to use the approval to expand K-CAB's presence in Brazil and strengthen its business competitiveness across Latin America.
The active pharmaceutical ingredient (API) for K-CAB supplied to Brazil will be manufactured at HK inno.N's Daeso plant. The facility received Good Manufacturing Practice (GMP) certification from ANVISA last year for the production and quality control of tegoprazan APIs.
HK inno.N plans to ensure stable production and supply of the drug's API, strengthening its supply infrastructure to support further global expansion.
In 2022, HK inno.N signed a technology transfer agreement for K-CAB with Brazilian pharmaceutical company Eurofarma, which operates in 24 countries. The drug will be marketed in Brazil under the local brand name TREV through Eurofarma.
K-CAB received approval for three indications: treatment of erosive gastroesophageal reflux disease, non-erosive gastroesophageal reflux disease and gastric ulcers.
"Marketing approval in Brazil once again demonstrates K-CAB's competitiveness in the global market," HK inno.N CEO Kwak Dal-won said. "We will work closely with our local partner to establish K-CAB as a new treatment option for patients in Brazil."
South Korea's 30th domestically developed new drug, K-CAB, was launched in March 2019. With its rapid onset of action and established long-term safety over six months of use, the drug recorded cumulative outpatient prescription sales of 1.0433 trillion won through the first half of this year, maintaining its leading position in South Korea's peptic ulcer treatment market.
K-CAB has signed technology transfer or finished-product export agreements in 55 overseas markets, including China, Southeast Asia and Latin America. It has received marketing approval in 25 countries, including South Korea, and has been launched in 22.